__NUXT_JSONP__("/drugs/Cofetuzumab_Pelidotin", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1869937-48-3",chebiId:b,chemicalFormula:b,definition:"An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2\u002FM phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.",fdaUniiCode:"249EAP69MT",identifier:"C123828",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129823","C1512"],synonyms:["ADC PF-06647020","ADC PF-7020","COFETUZUMAB PELIDOTIN",c,"Immunoglobulin G1, Anti-(human protein tyrosine kinase 7) (humanized Mus musculus clone hu24 gamma-chain), Disulfide with humanized Mus musculus clone hu24 kappa-chain, Dimer, Thioether with N-(((4-((N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl)amino)phenyl)methoxy)carbonyl)-2-methylalanyl-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(2-thiazolyl)ethyl)amino)propyl)-1-pyrrolidinyl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide","PF 06647020","PF 7020","PF-06647020","PF-7020","PF06647020","h6M24-vc0101"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FCofetuzumab_Pelidotin",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Cofetuzumab_Pelidotin","","Cofetuzumab Pelidotin","2021-10-30T13:30:07.623Z")));